Dasatinib (BMS-354825) is an oral, multitargeted inhibitor of tyrosine kinases, including BCR-ABL fusion protein, SRC family kinases (SRC, LCK, YES, FYN),
c-KIT, erythropoietin-producing hepatocellular receptor A2 (EPHA2), and platelet-derived growth factor receptor β (PDGFRβ).
In vitro studies have shown that dasatinib is active in leukemic cell lines representing variants of imatinib mesylate [
I0936] sensitive and resistant disease. Dasatinib inhibits the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. (The product is for research purpose only.)